Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents
Platelets are central to inflammation-related manifestations of cardiovascular diseases
(CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A 2 …
(CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A 2 …
Low-dose aspirin for the prevention of atherothrombosis
C Patrono, LA García Rodríguez… - … England Journal of …, 2005 - Mass Medical Soc
This review considers the role of low-dose aspirin for the prevention of atherothrombosis,
discussing the molecular mechanism of action of aspirin as well as clinical and …
discussing the molecular mechanism of action of aspirin as well as clinical and …
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology …
Writing Committee Members, EM Antman, DT Anbe… - Circulation, 2004 - Am Heart Assoc
D. Medication Assessment............................................ 610 1. Beta Blockers....................................
................. 609 2. Nitroglycerin...................................................... 610 3. Inhibition of the Renin …
................. 609 2. Nitroglycerin...................................................... 610 3. Inhibition of the Renin …
[HTML][HTML] Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes
RA DeFronzo, R Eldor, M Abdul-Ghani - Diabetes care, 2013 - ncbi.nlm.nih.gov
Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European …
L Rydén, E Standl, M Bartnik… - European heart …, 2007 - academic.oup.com
Task Forces, expert groups, or consensus panels. The chosen experts in these writing
panels are asked to provide disclosure statements of all relationships they may have, which …
panels are asked to provide disclosure statements of all relationships they may have, which …
Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
S Silber, P Albertsson, FF Avilés… - European heart …, 2005 - academic.oup.com
In patients with stable CAD, PCI can be considered a valuable initial mode of
revascularization in all patients with objective large ischaemia in the presence of almost …
revascularization in all patients with objective large ischaemia in the presence of almost …
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …
intersubject variability. To determine whether frequent functional variants of genes coding for …
Platelet-neutrophil-interactions: linking hemostasis and inflammation
A Zarbock, RK Polanowska-Grabowska, K Ley - Blood reviews, 2007 - Elsevier
Platelets are essential for primary hemostasis, but they also play an important pro-
inflammatory role. Platelets normally circulate in a quiescent state. Upon activation, platelets …
inflammatory role. Platelets normally circulate in a quiescent state. Upon activation, platelets …
The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD)
Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose
RA DeFronzo, M Abdul-Ghani - The American journal of cardiology, 2011 - Elsevier
Individuals with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are
at high risk, not only to develop diabetes mellitus, but also to experience an adverse …
at high risk, not only to develop diabetes mellitus, but also to experience an adverse …